Anti-VEGF × Anti-ANG2 Bispecific Antibody (NANO-L001)
Recombinant Anti-VEGFA & Anti-Ang2 Bispecific Antibody (Bi-Single Domain Antibody) comprises two monomeric VH-like binding entities of different specificities that are fused to each other in a bivalent-bispecific manner. Bi-Single Domain Antibody is only consisted of the VHHs. The loss of light chain and constant fragment in bi-Single Domain Antibody does not eliminate their functional antigen-binding capacity, but even endows them non-substitutable advantage in application. This BsAb is capable of inhibiting two proangiogenics and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone. It was designed for the treatment of diseases that are associated with VEGFA- and/or Ang2- mediated effects on angiogenesis are disclosed.
Specifications
- Targets
- VEGF & ANG2
- Type
- Bi-Single Domain Antibody
- Expression Host
- CHO
- Species Reactivity
- Human
- Target 1
- VEGF
- Host
- Llama
- Target 2
- ANG2
- Host
- Llama
- Purity
- >95% judged by SDS-PAGE under reducing condition
- Applications
- FuncS, Promising therapeutic agent
- Related Disease
- Diseases that are associated with VEGFA- and/or Ang2- mediated effects on angiogenesis are disclosed
Targets
- Target 1
- VEGF
- Gene ID
- 7422
- UniProt ID
- P15692
- Alternative Names
- VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; vascular permeability factor
- Target 2
- ANG2
- Gene ID
- 285
- UniProt ID
- O15123
- Alternative Names
- ANGPT2; angiopoietin 2; ANG2; AGPT2; angiopoietin-2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: